TaiGen Biopharmaceuticals Holdings 대차 대조표 상태

재무 상태 기준 확인 6/6

TaiGen Biopharmaceuticals Holdings 의 총 주주 지분은 NT$1.1B 이고 총 부채는 NT$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 NT$1.2B 및 NT$108.9M 입니다.

주요 정보

부채 비율

NT$0

부채

이자 보상 비율	n/a
현금	NT$1.06b
주식	NT$1.11b
총 부채	NT$108.94m
총 자산	NT$1.22b

최근 재무 상태 업데이트

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04

Recent updates

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04

재무 상태 분석

단기부채: 4157 의 단기 자산 ( NT$1.1B )이 단기 부채( NT$58.4M ).

장기 부채: 4157 의 단기 자산( NT$1.1B )이 장기 부채( NT$50.6M ).

부채 대 자본 내역 및 분석

부채 수준: 4157 부채가 없습니다.

부채 감소: 4157 5년 전에 부채가 없었습니다.

부채 범위: 4157 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 4157 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

TaiGen Biopharmaceuticals Holdings 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Recent updates

Third quarter 2024 earnings released: NT$0.10 loss per share (vs NT$0.012 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.09 (vs NT$0.014 in 2Q 2023)

First quarter 2024 earnings released: NT$0.01 loss per share (vs NT$0.07 loss in 1Q 2023)

Full year 2023 earnings released: EPS: NT$0.19 (vs NT$0.33 loss in FY 2022)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: NT$0.01 loss per share (vs NT$0.015 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.015 (vs NT$0.14 loss in 2Q 2022)

Full year 2022 earnings released: NT$0.33 loss per share (vs NT$1.08 profit in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.14 loss per share (vs NT$1.54 profit in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: NT$0.05 loss per share (vs NT$0.061 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.08 (vs NT$0.56 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: NT$0.19 loss per share (vs NT$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.54 (vs NT$0.14 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.10 loss in 1Q 2020)

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Full year 2020 earnings released: NT$0.56 loss per share (vs NT$0.41 loss in FY 2019)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 27, 2021

New 90-day low: NT$17.90

New 90-day low: NT$21.35

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

TaiGen Biotechnology Company, Limited Partners with GPCR Therapeutics, Inc. to Develop Burixafor & Taigexyn(R)

Third quarter 2020 earnings released: NT$0.14 loss per share

First half earnings released

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기